Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ZolgensmaⓇ - Gene Therapy Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03505099 SPR1NT (COAV101A12303) Spinal muscular atrophy Phase 3 30 [2 copies of SMN2] Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit [3 copies of SMN2] Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit Open-label, single-arm, single-dose, intravenous NCT03837184 STRIVE Asia Pacific (COAV101A12304) Type 1 spinal muscular atrophy Phase 3 2 Proportion of participants sitting without support Open-label, single-arm, single-dose, intravenous Patients with spinal muscular atrophy Type 1 H2-2021 Pre-symptomatic patients with spinal muscular atrophy and multiple copies SMN2 H2-2021 (3-copy cohort) Final study results of two-copy cohort were presented as late-breaker oral presentation at EAN Jun 22 2021; final study results of three-copy cohort to be presented at 2022 congress. TBD 91 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation